| Source publication date | |
|---|---|
| Reported on Testosterone Science | |
| Outlet type | Medical and professional news |
| Population | Men |
| Source | BriefGlance |
| URL | briefglance.com/articles/marius-pharma-tests-kyzatrex-in-seniors-targeting-untapped-market (opens in a new tab) |
Specific Claim Evaluated
Testosterone therapy was not associated with an increased risk of major adverse cardiovascular events, but pulmonary embolism and atrial fibrillation were more frequent in the treatment group.
Primary Research Supporting or Contradicting the Claim
TRAVERSE found testosterone noninferior to placebo for major adverse cardiac events, with a higher incidence of atrial fibrillation, acute kidney injury and pulmonary embolism (Lincoff et al., 2023). Kyzatrex, an oral testosterone undecanoate, was approved by the FDA on July 27, 2022 (OptumRx, 2022).
Corrected Evidence-Based Interpretation
The article is correct. The ongoing study is open label, 6 months long and enrolls 50 men, so it will provide limited safety information for men aged 65 to 80 years.
Rationale for Grade
The article reports both the reassuring and adverse TRAVERSE findings, reproduces the FDA position on age-related decline and describes the planned study as hypothesis-generating. The unsourced figure that prescriptions in men over 60 have quadrupled is not the central claim and does not alter the accuracy of the safety reporting.
References
- Lincoff AM, Bhasin S, Flevaris P, Mitchell LM, Basaria S, Boden WE, Cunningham GR, Granger CB, Khera M, Thompson IM, et al. Cardiovascular safety of testosterone-replacement therapy. N Engl J Med. 2023;389(2):107-117. PMID
Supporting excerpt: "noninferior to placebo with respect to the incidence of major adverse cardiac events" - OptumRx. Kyzatrex (testosterone undecanoate): new drug approval. Drug approval bulletin, July 28, 2022.
Supporting excerpt: "On July 27, 2022, the FDA approved Marius Pharmaceuticals' Kyzatrex"